Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/197593
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | A clinical approach for the use of VIP axis in inflammatory and autoimmune diseases |
Autor: | Martínez, Carmen; Juarranz, Yasmina; Gutiérrez-Cañas, Irene; Carrión, Mar; Pérez-García, Selene; Villanueva-Romero, Raúl; Castro, David; Lamana, Amalia; Mellado, Mario CSIC ORCID ; González-Álvaro, Isidoro; Gomariz, Rosa P. | Palabras clave: | vasoactive intestinal peptide VPAC1 receptor VPAC2 receptor rheumatic diseases Inflammatory bowel diseases central nervous system diseases type 1 diabetes Sjögren’s syndrome Biomarkers |
Fecha de publicación: | 20-dic-2019 | Editor: | Multidisciplinary Digital Publishing Institute | Citación: | International Journal of Molecular Sciences 21(1): 65 (2019) | Resumen: | The neuroendocrine and immune systems are coordinated to maintain the homeostasis of the organism, generating bidirectional communication through shared mediators and receptors. Vasoactive intestinal peptide (VIP) is the paradigm of an endogenous neuropeptide produced by neurons and endocrine and immune cells, involved in the control of both innate and adaptive immune responses. Exogenous administration of VIP exerts therapeutic effects in models of autoimmune/inflammatory diseases mediated by G-protein-coupled receptors (VPAC1 and VPAC2). Currently, there are no curative therapies for inflammatory and autoimmune diseases, and patients present complex diagnostic, therapeutic, and prognostic problems in daily clinical practice due to their heterogeneous nature. This review focuses on the biology of VIP and VIP receptor signaling, as well as its protective effects as an immunomodulatory factor. Recent progress in improving the stability, selectivity, and effectiveness of VIP/receptors analogues and new routes of administration are highlighted, as well as important advances in their use as biomarkers, contributing to their potential application in precision medicine. On the 50th anniversary of VIP’s discovery, this review presents a spectrum of potential clinical benefits applied to inflammatory and autoimmune diseases. | Versión del editor: | https://doi.org/10.3390/ijms21010065 | URI: | http://hdl.handle.net/10261/197593 | DOI: | 10.3390/ijms21010065 | E-ISSN: | 1422-0067 |
Aparece en las colecciones: | (CNB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
clinical_VIP_axis_inflammatory_autoimmune_diseases.pdf | 2,9 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
25
checked on 11-abr-2024
SCOPUSTM
Citations
32
checked on 16-abr-2024
WEB OF SCIENCETM
Citations
30
checked on 27-feb-2024
Page view(s)
205
checked on 23-abr-2024
Download(s)
219
checked on 23-abr-2024